Abstract
Ozanimod (ZEPOSIA(R); Celgene Corporation) is a novel, orally administered sphingosine 1-phosphate (S1P) receptor modulator. In March 2020, the US FDA......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
